Databases
Hi Lani and Cynthia,
I agree, having an entirely separate database containing all HER2s is the goal. I'm asking whether there is any reason to examine or consider what went into creating the legal and practical aspects of those already-existing HER2 databases, as well as any possibility of accessing and utilizing any of the basic data already collected in those databases (1,000 as you mentioned for metastatic HER2's and in the case of the TEACH trial, more tumors obtained prior to initial treatment for several thousand early stage HER2's who have never had Herceptin but have completed chemotherapy and are NED). Even just using the TEACH trial example to consider what went into the establishment of the international advisory panel of HER2 oncologists, or the way in which they established the specifics for their tumor collection, could be helpful in creating our general HER2 registry. Does that not make sense? Or is the raw data from tumors and histories (not the conclusions from ongoing trial study) as well as the structure that those two trials have put together entirely inaccessible and/or completely useless to us in our efforts?
AlaskaAngel
|